GT Biopharma, Inc. (GTBP)
Nasdaq: GTBP · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 1995
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Mar 2, 2026 | Feb 21, 2025 | Mar 26, 2024 | Mar 30, 2023 | Mar 28, 2022 | Apr 16, 2021 | Mar 27, 2020 | Mar 29, 2019 | Mar 1, 2018 | Mar 31, 2017 |
| Revenue | · | · | · | · | · | 0 | 0 | · | 0 | 0 |
| Cost of revenue | · | · | · | · | · | · | · | · | 0 | 0 |
| Gross profit | · | · | · | · | · | · | · | · | 0 | 0 |
| Research and development | 3,472 | 5,798 | 6,466 | 8,811 | 9,591 | 485 | 1,667 | 9,067 | 1,068 | 975 |
| Selling, general and administrative | 8,950 | 8,566 | 7,110 | 12,446 | 47,924 | 6,279 | 9,790 | 12,487 | 134,502 | 8,399 |
| Total operating expenses | · | · | 13,576 | 21,257 | 57,515 | · | 16,056 | 250,069 | 135,570 | 9,374 |
| Operating income | -12,422 | -14,364 | -13,576 | -21,257 | -57,515 | -6,764r | 16,056r | -250,069 | -135,570 | -9,374 |
| Interest expense | 127 | · | 213 | 8 | 718 | -3,003 | -2,128r | 9,117 | 8,602 | 6,555 |
| Interest and investment income | 123 | 402 | 780 | 292 | 38 | · | · | · | · | · |
| Other income (expense), net | 156 | · | 20 | · | 38 | · | · | · | · | · |
| Total non-operating income (expense) | -15,932 | 1,202 | 5,979 | 373 | -498 | -21,532r | 22,591r | -9,117 | -8,602r | 19,142r |
| Income before income taxes | · | · | · | · | · | · | -38,647 | -259,186 | -144,172r | 9,768r |
| Income tax expense | · | · | · | · | · | · | 0 | 0 | 0 | 0 |
| Net income including non-controlling interests | · | · | · | · | -58,013 | -28,296 | · | · | · | · |
| Net income to non-controlling interests | · | · | · | · | · | · | · | · | 0 | 0 |
| Net income | -28,354 | -13,162 | -7,597 | -20,884 | -58,013 | -28,296 | -38,647 | -259,186 | -144,172r | 9,768r |
| Net income to common shareholders | -34,449 | -13,162 | · | · | · | · | · | · | · | · |
| Earnings per share, basic | -6.68 | -6.94 | -5.64 | -19.66r | -2.06 | · | · | -5.16 | -8.60r | 2.0324rb |
| Earnings per share, diluted | -6.68 | -6.94 | -5.64 | -19.66 | · | · | · | -0.0875b | -0.1458rb | 2.0324rb |
| Earnings per share, basic and diluted | · | · | · | · | -2.06 | -6.45 | -0.01r | -0.0875b | -0.1458b | 4.3729b |
| Weighted average shares, basic | 5,513,255 | 1,897,375 | 1,347,713 | 1,062,267r | 28,155,624 | · | · | 2,964,160b | 989,371rb | 4,806,140rb |
| Weighted average shares, diluted | 5,513,255 | 1,897,375 | 1,347,713 | 1,062,267 | · | 4,385,222 | 3,383,941,000rb | 2,964,160b | 989,371rb | 4,806,140rb |
| Weighted average shares, basic and diluted | · | · | · | · | 28,155,624 | 4,385,222 | · | · | · | 4,804,155b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 59-for-1 split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:Revenues
us-gaap:SalesRevenueNetCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InterestIncomeOtherOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income to non-controlling interests the share that belongs to minority holders
us-gaap:NetIncomeLossAttributableToNoncontrollingInterestNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted